SX-682

Phase 2Small molecule

SSyntrix Biosystems, Inc.

SX-682 is one of 198 small molecule programs targeting Leptomeningeal Disease (LMD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

197

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leptomeningeal Disease (LMD)Recruiting

Head and Neck CancerNot yet recruiting

Pancreas CancerActive, not recruiting

Metastatic MelanomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Myelodysplastic SyndromeRecruiting

Prostate CancerRecruiting

Leptomeningeal Disease (LMD)Phase 1

Recruiting

Head and Neck CancerPreclinical

Not yet recruiting

Pancreas CancerPhase 2

Active, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 1

Active, not recruiting

Myelodysplastic SyndromePhase 1

Recruiting

Prostate CancerPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Zoladex

TTerSera Therapeutics LLC

Phase 3

35 2

Cabometyx

Bristol-Myers Squibb

Phase 3

12 3

Rubraca

Bristol-Myers Squibb

Phase 3

9 4

Verzenio

Eli Lilly

Phase 3

5 5

Truqap

AstraZeneca

Phase 3

2 6

Provenge

PProstate Oncology Specialists, Inc.

Phase 3

21 7

SX-682

SSyntrix Biosystems, Inc.

Phase 2

1 8

Trexall

Jazz Pharmaceuticals

Preclinical

—9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Pancreatic Ductal Adenocarcinoma

NCT04477343

Q2 2027

Phase 1Active, not recruiting

Metastatic Melanoma

NCT03161431

Q2 2028

Phase 2Recruiting

Prostate Cancer

NCT06228053

Q1 2029

Phase 1Recruiting

Myelodysplastic Syndrome

NCT04245397

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT04574583·12 enrolled

Prostate Cancer1 trial

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Recruiting·SSyntrix Biosystems, Inc.·Phase 2·NCT06228053·53 enrolled

Pancreas Cancer1 trial

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Active, not recruiting·LLei Zheng·Phase 2·NCT05604560·25 enrolled

Myelodysplastic Syndrome1 trial

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Recruiting·SSyntrix Biosystems, Inc.·Phase 1·NCT04245397·151 enrolled

Metastatic Melanoma1 trial

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Active, not recruiting·SSyntrix Biosystems, Inc.·Phase 1·NCT03161431·77 enrolled

5 more indications

Head and Neck Cancer1 trial

Phase I/II Trial of Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Not yet recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07667400·120 enrolled

Metastatic Colorectal Cancer1 trial

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT06149481·60 enrolled

Leptomeningeal Disease (LMD)1 trial

A Phase Ib Trial of SX-682 (CXCR1/2 Inhibitor) Combined With Proton Craniospinal Irradiation for Patients With Leptomeningeal Disease

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07814352·40 enrolled

Castrate Resistant Prostate Cancer1 trial

ASpiRE: A Proof-of-mechanism and Proof-of-concept Clinical Trial Evaluating the Safety, Tolerability, Biological and Anti-tumour Activity of Apalutamide With Dual CXCR1 and CXCR2 Blockade by SX-682 for Men Suffering From Metastatic Castration-resistant Prostate Cancer (mCRPC)

Recruiting·IInstitute of Cancer Research, United Kingdom·Preclinical·NCT07002320·78 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting·UUniversity of Rochester·Phase 1·NCT04477343·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for SX-682. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SX-682 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SX-682. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Syntrix Biosystems, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSyntrix Biosystems, Inc.

SX-682

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q2 2028

Q1 2029

Trials by Indication[1]

Advanced Solid Tumors1 trial

Prostate Cancer1 trial

Pancreas Cancer1 trial

Myelodysplastic Syndrome1 trial

Metastatic Melanoma1 trial

Head and Neck Cancer1 trial

Metastatic Colorectal Cancer1 trial

Leptomeningeal Disease (LMD)1 trial

Castrate Resistant Prostate Cancer1 trial

Pancreatic Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News